First Author: M.Cesena MEXICO
Co Author(s):
Purpose:
Prospective clinical study into the safety and efficacy of the treatment of presbyopic hyperopes with the Supracor excimer LASIK algorithm
Setting:
LASER OCULAR HIDALGO
Methods:
In this single site, multi-surgeon, clinical study, 35 presbyopic hyperopes were treated with the Supracor presbyopic LASIK procedure. The non-dominant eye was treated with Supracor using the Technolas 217P excimer laser (Technolas Perfect Vision). Where needed, the fellow eye was treated with a standard LASIK procedure. Over a one year follow-up period, uncorrected near and distance visual acuity (UNVA, UDVA) and distance corrected near and best corrected distance visual acuity (DCNVA, BSCVA), safety, refraction and patient satisfaction were assessed.
Results:
Mean patient age was 50.1 years (range 45-60 years). Pre-operative mean manifest spherical equivalent (MRSE) and mean cylinder were 1.26D and 0.51D. At 6 months post-operatively, MRSE and cylinder were -0.73D and 0.38D, respectively. At 6 months post-op, 77% achieved monocular UNVA of 0.8 or better and 86% had binocular UNVA of 0.8. For binocular UDVA, 100% were 0.8 or better and 87% were 1.0. 100% patients had monocular BSCVA of 0.8 or better and 90% were 1.0. The patient questionnaire found a high level of patient satisfaction. Further one year post-op data will be presented.
Conclusions:
Treatment of presbyopic hyperopic patients with the SUPRACOR LASIK procedure is safe and effective treatment, resulting in a high level of spectacle independence. FINANCIAL DISCLOSURE?: ... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented
Please wait while information is loading.
